Factor XIa inhibitors emerge as safer stroke prevention, cutting harmful clots without excess bleeding—see which oral and IV drugs reach phase 3. This episode, titled ‘The Emerging Role of Factor XIa ...
The factor XIa inhibitor asundexian combined with standard antiplatelet therapy reduced the risk for recurrent ischemic stroke compared to antiplatelet therapy alone, without increasing bleeding, ...
Bristol Myers Squibb and Johnson & Johnson have begun an educational campaign about the factor XIa pathway, laying the groundwork for a launch that could follow phase 3 readouts expected this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results